Curis (CRIS) News Today $2.12 +0.04 (+1.92%) As of 05/20/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRIS Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Curis' (CRIS) Buy Rating Reaffirmed at HC WainwrightMay 21 at 1:57 AM | americanbankingnews.comCuris (NASDAQ:CRIS) Coverage Initiated at StockNews.comMay 16, 2025 | americanbankingnews.comCURIS Earnings Preview: Recent $CRIS Insider Trading, Hedge Fund Activity, and MoreMay 9, 2025 | nasdaq.comCuris’s Strategic Clinical Advancements and Positive Regulatory Feedback Underpin Buy RatingMay 8, 2025 | tipranks.comEarnings call transcript: Curis Inc. Q1 2025 sees stock surge despite lossesMay 8, 2025 | uk.investing.comCuris highlights progress in lymphoma and AML trials with expanded patient enrollmentMay 7, 2025 | msn.comCuris Inc (CRIS) Q1 2025 Earnings Call Highlights: Financial Improvements and Strategic DevelopmentsMay 7, 2025 | finance.yahoo.comCuris Inc. Reports Q1 2025 Progress and FinancialsMay 7, 2025 | tipranks.comCuris, Inc.: Curis Provides First Quarter 2025 Business UpdateMay 6, 2025 | finanznachrichten.deCuris Inc. Earnings Call: Clinical Advances Amid Cash ConcernsMay 6, 2025 | tipranks.comCuris Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | CRIS Stock NewsMay 6, 2025 | gurufocus.comCuris Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | CRIS Stock NewsMay 6, 2025 | gurufocus.comCuris Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)May 6, 2025 | investing.comCuris Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)May 6, 2025 | prnewswire.comCuris, Inc. (CRIS) Advances Emavusertib Studies with Positive DataMay 6, 2025 | gurufocus.comCuris, Inc. (CRIS) Q1 2025 Earnings Call TranscriptMay 6, 2025 | seekingalpha.comCuris Provides First Quarter 2025 Business Update | CRIS Stock NewsMay 6, 2025 | gurufocus.comCuris Inc (CRIS) Q1 2025 Earnings: EPS of -$1.25 Misses Estimates, Revenue of $2.4M Falls ShortMay 6, 2025 | gurufocus.comCuris (CRIS) Strengthens Leadership with New Chief Medical Officer | CRIS Stock NewsMay 6, 2025 | gurufocus.comCuris Provides First Quarter 2025 Business UpdateMay 6, 2025 | gurufocus.comCuris (CRIS) Expands Leadership and Advances Clinical Studies | CRIS Stock NewsMay 6, 2025 | gurufocus.comCuris Provides First Quarter 2025 Business UpdateMay 6, 2025 | prnewswire.comCuris Q1 2025 Earnings PreviewMay 5, 2025 | msn.com6CRIS : Earnings Outlook For CurisMay 5, 2025 | benzinga.comCuris to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on May 6, 2025April 29, 2025 | prnewswire.comCuris’s Strategic Advancements and Promising Outlook in IRAK4 Inhibitor Space Drive Buy RatingApril 14, 2025 | tipranks.comTruist Financial Keeps Their Buy Rating on Curis (CRIS)April 10, 2025 | markets.businessinsider.comAnalyst Forecasts For Curis, Inc. (NASDAQ:CRIS) Are Surging HigherApril 3, 2025 | finance.yahoo.comCuris to Present at Upcoming Healthcare Conference in AprilApril 2, 2025 | prnewswire.comCuris reports Q4 EPS ($1.25) vs. ($2.03) last yearApril 2, 2025 | markets.businessinsider.comCuris Stock Price, Quotes and ForecastsApril 1, 2025 | benzinga.comCuris price target lowered to $16 from $20 at H.C. WainwrightApril 1, 2025 | markets.businessinsider.comCuris, Inc. (NASDAQ:CRIS) Just Reported Full-Year Earnings And Analysts Are Lifting Their EstimatesApril 1, 2025 | finance.yahoo.comCuris, Inc. (NASDAQ:CRIS) Q4 2024 Earnings Call TranscriptApril 1, 2025 | msn.comCuris stock plunges to 52-week low at $1.97 amid market challengesApril 1, 2025 | investing.comCuris, Inc.: Curis Provides Fourth Quarter 2024 Business UpdateApril 1, 2025 | finanznachrichten.deCuris’s Promising Clinical Developments and Strategic Path to Accelerated Approval Boost Buy RatingApril 1, 2025 | tipranks.comCuris Inc (CRIS) Q4 2024 Earnings Call Highlights: Financial Improvements and Promising ...April 1, 2025 | gurufocus.comQ4 2024 Curis Inc Earnings Call TranscriptApril 1, 2025 | gurufocus.comCuris Inc. Reports Q4 2024 Progress and FinancialsMarch 31, 2025 | tipranks.comCuris targets accelerated approval for emavusertib in PCNSL with 12-18 month enrollment timelineMarch 31, 2025 | msn.comCuris, Inc. (CRIS) Q4 2024 Earnings Call TranscriptMarch 31, 2025 | seekingalpha.comCuris Inc (CRIS) Q4 2024 Earnings: EPS of -$1.25 Beats Estimate, Revenue Surges to $3.3 MillionMarch 31, 2025 | gurufocus.comCuris eyes accelerated approval for cancer drug emavusertibMarch 31, 2025 | investing.comCuris Provides Fourth Quarter 2024 Business UpdateMarch 31, 2025 | prnewswire.comCuris to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on March 31, 2025March 28, 2025 | prnewswire.comCuris Inc.March 18, 2025 | wsj.comCuris Inc faces potential Nasdaq delistingMarch 1, 2025 | uk.investing.comCuris Shares Gain on Results From Leukemia-Treatment StudyJanuary 2, 2025 | marketwatch.comCuris files to sell 2.4M shares of common stock for holdersDecember 24, 2024 | markets.businessinsider.com Get Curis News Delivered to You Automatically Sign up to receive the latest news and ratings for CRIS and its competitors with MarketBeat's FREE daily newsletter. Email Address CRIS Media Mentions By Week CRIS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CRIS News Sentiment▼0.000.65▲Average Medical News Sentiment CRIS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CRIS Articles This Week▼32▲CRIS Articles Average Week Get Curis News Delivered to You Automatically Sign up to receive the latest news and ratings for CRIS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Dominari News Today Fortress Biotech News Today SAB Biotherapeutics News Today Bolt Biotherapeutics News Today Molecular Templates News Today Amgen News Today Gilead Sciences News Today Vertex Pharmaceuticals News Today Regeneron Pharmaceuticals News Today Alnylam Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CRIS) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Curis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Curis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
